Respiratory syncytial virus and adult respiratory prevention
Research activity centres on RSV vaccines for older adults, solid organ transplant recipients, and adults at increased risk of respiratory disease, with attention to immune response, safety, and vaccine co-administration.
- RSVPreF3 OA
- RSV-A and RSV-B immunity
- Transplant recipients
- Co-administration with pneumococcal and COVID-19 vaccines
The sponsor also studies persistence of protection and revaccination strategies in populations with heightened vulnerability to lower respiratory tract disease.
Herpes zoster, varicella, and herpes simplex
Another major area is prevention of varicella-zoster virus disease across children, adolescents, and older adults, including work in immunocompromised paediatric populations and studies of herpes simplex virus interventions.
- Herpes zoster prevention
- Varicella vaccination
- Immunocompromised children and adolescents
- Genital herpes prevention
Trial activity also includes evaluation of immune responses in healthy children and older adults, with interest in long-term protection and disease reduction.
Meningococcal disease and multivalent bacterial vaccines
The sponsor funds research in meningococcal prevention, including MenB and MenACWY coverage, with studies focused on immune responses in adolescents and broader protection against invasive disease.
- Invasive meningococcal disease
- MenB vaccine responses
- MenABCWY formulations
- Serogroups A, C, W, and Y
These programmes examine responses to multivalent meningococcal candidates and booster vaccination in healthy participants.
Influenza, measles, mumps, rubella, and chickenpox
GlaxoSmithKline Biologicals maintains a strong focus on established paediatric and adult immunisation areas, including influenza vaccines and combined MMR and varicella products for children and healthy volunteers.
- Influenza prevention
- MMR and MMRV vaccination
- Paediatric immunisation
- Healthy volunteers
Research in this area includes comparisons of immune responses across vaccine formulations and routes of administration.
Chronic hepatitis B, urinary tract infections, and cardiovascular and cognitive outcomes
The sponsor also supports programmes in chronic hepatitis B, urinary tract infection prevention, and broader outcome studies linked to vaccination, including dementia and major adverse cardiovascular events.
- Chronic hepatitis B
- UTI vaccine development
- Dementia risk
- Cardiovascular outcomes
Work in these domains reflects interest in infectious disease prevention alongside age-related and long-term clinical outcomes.
